Pharmicell Reports 48.3 Billion KRW in Cumulative Q3 Sales... Nucleoside Achieves Record High Performance

[Asia Economy Reporter Hyungsoo Park] Pharmicell announced on the 8th that its sales in the third quarter of this year reached 17.3 billion KRW, a 31% increase compared to the same period last year. The cumulative sales up to the third quarter amounted to 48.3 billion KRW, a 23% increase compared to the same period last year, and operating profit reached 9.7 billion KRW, an 18% increase.

Pharmicell attributed the strong performance to increased sales in the biochemical division. The cumulative sales of the biochemical division in the third quarter reached 47 billion KRW, accounting for 97% of total sales.

Sales of nucleosides, which are raw materials used in RNA therapeutics and genetic diagnostic reagents, recorded 21.8 billion KRW, exceeding the previous year's annual performance.

A Pharmicell official stated, "The operation of the biochemical division's second plant has also officially started," adding, "From the fourth quarter of this year, the production volume of nucleosides is expected to increase, leading to higher sales."

He continued, "The biomedical division reduced its deficit compared to the previous year," and said, "We have signed a medical tourism agreement with university hospitals to promote the excellence of stem cell therapeutics and plan to continue attracting foreign patients.”

This content was produced with the assistance of AI translation services.